The digital health ecosystem is witnessing the commercial maturation of intermediated business models, yet a critical distinction must be drawn between distribution channels and value origination. The business-to-business-to-consumer (B2B2C) model, characterised by partnerships between HealthTech companies and enterprise payers (employers, insurers), has become the default go-to-market strategy, primarily due to its ability to scale adoption and mitigate high customer acquisi

The advisory landscape for European Medical Technology (MedTech) Mergers and Acquisitions (M&A) is distinguished by a structural bifurcation across transactional size and specialised focus. The market influence is segmented into three distinct classes: Tier 1 Global Banks, which dominate based on aggregate transaction value due to their capacity to underwrite and execute multi-billion-dollar strategic acquisitions; Tier 2 Integrated Firms, which drive high deal volume and pro

The UK HealthTech mergers and acquisitions (M&A) market in 2025 is characterised by a "cautious yet discernible rebound". While global digital health funding has seen a decline, the European market, particularly within the UK, has demonstrated remarkable resilience, defying global trends with a significant surge in deal activity. This momentum is not uniform, however; it is marked by a profound bifurcation that separates the market into two distinct categories.

The UK National Commission on the Regulation of AI in Healthcare has been established as a critical, non-statutory advisory body by the Medicines and Healthcare products Regulatory Agency (MHRA) to address the growing disparity between the rapid pace of artificial intelligence (AI) innovation and a legacy regulatory framework. Its mandate is to review existing regulations and provide a comprehensive set of recommendations for a new, rewritten rulebook for AI in healthcare, wh

Nelson Advisors invited to Judge the MedTech Startup Pitch Awards at MedTech Europe 2025. The MedTech Malta Startup Pitch is a platform for medical technology startups to showcase their innovative products, services, and solutions to a panel of judges and potential investors. This shall provide a unique opportunity for entrepreneurs to gain exposure, receive feedback, and secure funding for their ventures.

This report provides a definitive analysis for venture capital (VC) investment in the value-based care (VBC) healthtech sector. While VBC represents a profound and necessary paradigm shift with a multi-trillion-dollar market opportunity, it is not an environment for unsophisticated capital. The core finding is a qualified "yes": venture capital should strategically back VBC healthtech, but only by targeting specific business models and deploying patient capital with a deep

Subconscious vibro-tactile stimulation (VTS) represents a powerful, emerging modality within the HealthTech sector, positioned to transition from a specialised clinical tool to a ubiquitous component of personalised healthcare. Defined as the application of non-invasive mechanical vibration to the skin to modulate neural activity, VTS operates on an implicit level, leveraging the body's natural sensory and proprioceptive systems to effect therapeutic changes in the brain and

For High-Growth HealthTech Startups: When planning a fundraising or exit event, it is recommended to engage with a specialised boutique advisor like Nelson Advisors, with their "founders for founders" approach, they can offer a more tailored and empathetic perspective. Their deep understanding of the market niche and hands-on guidance can be more valuable for maximising shareholder value than the broad, standardised services of a larger generalist firm.

TIME has released its inaugural "World's Top HealthTech Companies 2025" list, in partnership with Statista. The ranking highlights 400 companies from over 25 countries across six market segments. The companies were evaluated based on a combination of financial performance, reputation analysis, and online engagement.

The current healthcare innovation economy presents a compelling and complex paradox for investors. The broader US healthcare venture capital fundraising landscape has experienced a significant decline, with the total for the first half of 2025 at just $3 Billion, a steep drop from the previous year. This puts the sector on track for its worst fundraising year in over a decade. This market contraction is largely attributed to economic and political uncertainty, coupled with a

Nelson Advisors Partner Lloyd Price will Chair the panel discussing the European HealthTech Investment Landscape, covering key questions such as: Which countries or regions in Europe are emerging as HealthTech hubs? Beyond the traditional powerhouses like the UK, Germany, and France, are there new centers of innovation, particularly in Central and Eastern Europe (CEE)? How are macroeconomic factors impacting the market? How are rising interest rates and inflation affecting d

European HealthTech Market Analysis - September 2025: Transition from Fragmented Point Solutions into Critical Healthcare Infrastructure....

The field of vagus nerve neuromodulation (VNN) is undergoing a profound transformation, moving beyond its established applications to emerge as a cornerstone of bioelectronic medicine. While vagus nerve stimulation (VNS) has long been a recognised treatment for refractory epilepsy and treatment-resistant depression, recent technological breakthroughs and landmark clinical trial results are expanding its therapeutic reach into a wide array of chronic inflammatory, neurological

Nelson Advisors LLP, a UK-based firm, is explicitly and exclusively focused on providing mergers and acquisitions (M&A) advisory services within the healthcare technology sector across the United Kingdom, Europe, and North America. The firm’s core value proposition is rooted in a distinctive "practitioner-led" approach. This model is a direct function of the synergistic partnership between its two co-founders, whose professional backgrounds combine extensive corporate finance

The European HealthTech and MedTech sectors are undergoing a profound transformation, moving from a fragmented, early-stage ecosystem to a mature, consolidating landscape ripe for sophisticated private equity (PE) strategies. This report serves as a strategic blueprint for PE firms aiming to capitalise on this evolution. The analysis reveals that the European digital health market has emerged as a global leader in funding growth, propelled by a strategic pivot towards fewer,